Plasma interferon alpha and the wasting syndrome in patients infected with the human immunodeficiency virus. 1995

J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri

UI MeSH Term Description Entries
D004614 Emaciation Clinical manifestation of excessive LEANNESS usually caused by disease or a lack of nutrition (MALNUTRITION). Emaciations
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013577 Syndrome A characteristic symptom complex. Symptom Cluster,Cluster, Symptom,Clusters, Symptom,Symptom Clusters,Syndromes
D015431 Weight Loss Decrease in existing BODY WEIGHT. Weight Reduction,Loss, Weight,Losses, Weight,Reduction, Weight,Reductions, Weight,Weight Losses,Weight Reductions
D015999 Multivariate Analysis A set of techniques used when variation in several variables are studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables. Analysis, Multivariate,Multivariate Analyses
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon

Related Publications

J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
April 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
September 2001, The Journal of clinical endocrinology and metabolism,
J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
January 1995, Hepato-gastroenterology,
J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
January 1996, Gastroenterologie clinique et biologique,
J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
July 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
February 2004, Antimicrobial agents and chemotherapy,
J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
September 1995, Ophthalmology,
J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
October 1991, Seminars in oncology,
J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
January 1994, Biotherapy (Dordrecht, Netherlands),
J Constans, and I Pellegrin, and J L Pellegrin, and E Peuchant, and M Simonoff, and C Sergeant, and H Fleury, and M Clerc, and B Leng, and C Conri
November 2018, International journal of STD & AIDS,
Copied contents to your clipboard!